Eculizumab treatment for renal failure in a pediatric patient with COVID-19.
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
19
06
2020
accepted:
03
09
2020
pubmed:
28
9
2020
medline:
18
12
2020
entrez:
27
9
2020
Statut:
ppublish
Résumé
While there are increasing reports of acute kidney injury among hospitalized adults with COVID-19, there is still limited information on renal complications associated with COVID-19 in children. The cause of kidney involvement in COVID-19 is likely multifactorial, and appears to involve a complex process, including complement dysregulation and thrombotic microangiopathy. We present a pediatric case of COVID-19 and renal failure due to thombotic microangiopathy, successfully treated with eculizumab.
Identifiants
pubmed: 32981025
doi: 10.1007/s40620-020-00858-2
pii: 10.1007/s40620-020-00858-2
pmc: PMC7519698
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Complement Inactivating Agents
0
eculizumab
A3ULP0F556
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1373-1376Commentaires et corrections
Type : CommentIn
Références
Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, Hazzan AD, Fishbane S, Jhaveri KD, Northwell COVID-19 Research Consortium & Northwell Nephrology COVID-19 Research Consortium (2020) Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 98(1):209–218. https://doi.org/10.1016/j.kint.2020.05.006
doi: 10.1016/j.kint.2020.05.006
pubmed: 32416116
pmcid: 32416116
Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S, COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group (2020) Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol 31(7):1380–1383. https://doi.org/10.1681/ASN.2020040419
doi: 10.1681/ASN.2020040419
pubmed: 32366514
Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals M, Huisman MV, Endeman H (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147. https://doi.org/10.1016/j.thromres.2020.04.041
doi: 10.1016/j.thromres.2020.04.041
pubmed: 32291094
pmcid: 7146714
Luo W, Yu H, Gou J, Li X et al (2020) Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints 2020, 2020020407
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007
doi: 10.1016/j.trsl.2020.04.007
pubmed: 32299776
pmcid: 7158248
Szilágyi A, Kiss N, Bereczki C et al (2013) The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transpl 28(9):2237–2245. https://doi.org/10.1093/ndt/gft198
doi: 10.1093/ndt/gft198
Ricklin D, Mastellos DC, Reis ES, Lambris JD (2018) The renaissance of complement therapeutics. Nat Rev Nephrol 14(1):26–47. https://doi.org/10.1038/nrneph.2017.156
doi: 10.1038/nrneph.2017.156
pubmed: 29199277
Cavero T, Rabasco C, Lopez A et al (2017) Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transpl 32(3):466–474. https://doi.org/10.1093/ndt/gfw453
doi: 10.1093/ndt/gfw453
Campbell CM, Kahwash R (2020) Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis? Circulation 141(22):1739–1741. https://doi.org/10.1161/CIRCULATIONAHA.120.047419
doi: 10.1161/CIRCULATIONAHA.120.047419
pubmed: 32271624
Diurno F, Numis FG, Porta G et al (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24(7):4040–4047. https://doi.org/10.26355/eurrev_202004_20875
doi: 10.26355/eurrev_202004_20875
pubmed: 32329881
NIH (2020) Eculizumab (Soliris) in Covid-19 infected patients (SOLID-C19). (Clinicaltrials.gov Identifier NCT04288713). https://clinicaltrials.gov/ct2/show/NCT04288713. Accessed 28 May 2020
Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H, Wang C, Liu L, Liu Y, Wang G, Yuan Z, Ren L, Wu Y, Chen Y (2020) Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv 2020.03.04.20031120. https://doi.org/10.1101/2020.03.04.20031120
CDC COVID-19 Response Team (2020) Coronavirus disease 2019 in Children—United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep 69:422–426. https://doi.org/10.15585/mmwr.mm6914e4
doi: 10.15585/mmwr.mm6914e4
pmcid: 7147903
CDC Health Alert Network (2020) Multisystem inflammatory syndrome in children associated with coronavirus disease 2019. https://emergency.cdc.gov/han/2020/han00432.asp . Accessed 28 May 2020
Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, Milner JD (2020) Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA. https://doi.org/10.1001/jama.2020.10374
doi: 10.1001/jama.2020.10374
pubmed: 33289824
pmcid: 7281352